慢性自发性荨麻疹的疾病管理和疾病修饰：新时代下的需求与展望

doi:10.35541/cjd.20240719

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (6): 503-507.doi: 10.35541/cjd.20240719

慢性自发性荨麻疹的疾病管理和疾病修饰：新时代下的需求与展望

宋志强杨显杰陈奇权

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2024-12-27 修回日期:2025-01-13 发布日期:2025-06-03
通讯作者: 宋志强 E-mail:drsongzq@tmmu.edu.cn

Disease management and modification in chronic spontaneous urticaria: needs and prospects in the new era

Song Zhiqiang, Yang Xianjie, Chen Qiquan

Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing 400038, China

Received:2024-12-27 Revised:2025-01-13 Published:2025-06-03
Contact: Song Zhiqiang E-mail:drsongzq@tmmu.edu.cn

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹（CSU）是一种临床常见且治疗充满挑战的慢性皮肤病，严重影响患者生活质量。随着对CSU发病机制认识的深入，治疗策略有了显著进步，治疗目标已从单一的症状控制转变为个性化精准诊疗、疾病全程管理和提升患者生活质量。本文总结CSU在疾病分型、评估、管理策略及疾病修饰理念方面的最新进展，旨在为提升CSU的临床管理提供新视角。

关键词: 荨麻疹, 慢性自发性荨麻疹, 表型, 内型, 患者报告结果测量, 生物标志物, 疾病修饰

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is a clinically common and therapeutically challenging chronic skin condition that significantly impairs patients' quality of life. With the increase in understanding of the pathogenesis of CSU, there has been a notable advancement in treatment strategies. The goals of treatment have shifted from symptomatic control to personalized precision medicine, comprehensive disease management, and enhancement of patients' quality of life. This article summarizes the latest advances in the subtyping, assessment, management strategies, and disease-modifying concepts of CSU, aiming to provide a new perspective for improving its clinical management.

Key words: Urticaria, Chronic spontaneous urticaria, Phenotype, Endotype, Patient-reported outcome measures, Biomarkers, Disease modification

宋志强杨显杰陈奇权. 慢性自发性荨麻疹的疾病管理和疾病修饰：新时代下的需求与展望[J]. 中华皮肤科杂志, 2025,58(6):503-507. doi:10.35541/cjd.20240719

Song Zhiqiang, Yang Xianjie, Chen Qiquan. Disease management and modification in chronic spontaneous urticaria: needs and prospects in the new era[J]. Chinese Journal of Dermatology, 2025, 58(6): 503-507.doi:10.35541/cjd.20240719

参考文献 36

［1］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［2］	Kolkhir P, Bonnekoh H, Metz M, et al. Chronic spontaneous urticaria: a review［J］. JAMA, 2024,332（17）:1464⁃1477. doi: 10.1001/jama.2024.15568.
［3］	Zuberbier T, Ensina LF, Giménez⁃Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment［J］. Lancet, 2024,404（10450）:393⁃404. doi: 10.1016/S0140⁃6736（24）00852⁃3.
［4］	Lang DM, Sheikh J, Joshi S, et al. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine［J］. Ann Allergy Asthma Immunol, 2025,134（4）:408⁃417. doi: 10.1016/j.anai.2024.10.026.
［5］	Sánchez J, Amaya E, Acevedo A, et al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors［J］. J Allergy Clin Immunol Pract, 2017,5（2）:464⁃470. doi: 10.1016/j.jaip.2016.09.029.
［6］	Chen Q, Yang X, Ni B, et al. Atopy in chronic urticaria: an important yet overlooked issue［J］. Front Immunol, 2024,15:1279976. doi: 10.3389/fimmu.2024.1279976.
［7］	Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review［J］. Autoimmun Rev, 2017,16（12）:1196⁃1208. doi: 10.1016/j.autrev.2017.10.003.
［8］	Sella JA, Ferriani M, Melo J, et al. TypeⅠ and typeⅡb autoimmune chronic spontaneous urticaria: using common clinical tools for endotyping patients with CSU［J］. J Allergy Clin Immunol Glob, 2023,2（4）:100159. doi: 10.1016/j.jacig. 2023.100159.
［9］	Elieh⁃Ali⁃Komi D, Metz M, Kolkhir P, et al. Chronic urticaria and the pathogenic role of mast cells［J］. Allergol Int, 2023,72（3）:359⁃368. doi: 10.1016/j.alit.2023.05.003.
［10］	Larenas⁃Linnemann D. Biomarkers of autoimmune chronic spontaneous urticaria［J］. Curr Allergy Asthma Rep, 2023,23（12）:655⁃664. doi: 10.1007/s11882⁃023⁃01117⁃7.
［11］	Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study［J］. Allergy, 2019,74（12）:2427⁃2436. doi: 10.1111/all.13949.
［12］	Altrichter S, Fok JS, Jiao Q, et al. Total IgE as a marker for chronic spontaneous urticaria［J］. Allergy Asthma Immunol Res, 2021,13（2）:206⁃218. doi: 10.4168/aair.2021.13.2.206.
［13］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［14］	Buttgereit T, Salameh P, Sydorenko O, et al. The 7⁃day recall period version of the urticaria control test⁃UCT7［J］. J Allergy Clin Immunol, 2023,152（5）:1210⁃1217. doi: 10.1016/j.jaci. 2023.03.034.
［15］	Cherrez⁃Ojeda I, Bousquet J, Giménez⁃Arnau A, et al. Patient⁃reported outcome measures in atopic dermatitis and chronic urticaria are underused in clinical practice［J］. J Allergy Clin Immunol Pract, 2024,12（6）:1575⁃1583. doi: 10.1016/j.jaip. 2024.03.050.
［16］	Bernstein JA, Apfelbacher C, Chu DK, et al. Patient⁃reported outcome measures in chronic spontaneous urticaria, angioedema, and atopic dermatitis［J］. J Allergy Clin Immunol Pract, 2024,12（10）:2583⁃2590. doi: 10.1016/j.jaip.2024.08.021.
［17］	Neisinger S, Sousa Pinto B, Ramanauskaite A, et al. CRUSE® ⁃an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria［J］. Clin Transl Allergy, 2024,14（1）:e12328. doi: 10.1002/clt2.12328.
［18］	Sousa⁃Pinto B, Ramanauskaite A, Neisinger S, et al. Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: a CRUSE® mobile health study［J］. Allergy, 2025,80（3）:750⁃761. doi: 10.1111/all.16371.
［19］	Carvallo A, Veleiro B, Sabaté⁃Brescó M, et al. Serum amyloid A as a potential biomarker for disease activity in chronic spontaneous urticaria［J］. J Allergy Clin Immunol Pract, 2024,12（1）:195⁃200. doi: 10.1016/j.jaip.2023.09.004.
［20］	Jian X, Hou G, Li L, et al. Identification of pyruvic and maleic acid as potential markers for disease activity and prognosis in chronic urticaria［J］. J Allergy Clin Immunol, 2024,154（2）:412⁃423. doi: 10.1016/j.jaci.2024.01.032.
［21］	Ridge K, Moran B, Alvarado⁃Vazquez PA, et al. Lin-CD117+
	CD34+FcεRⅠ + progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti⁃IgE therapy［J］. Allergy, 2024,79（9）:2423⁃2434. doi: 10.1111/all.16127.
［22］	Ji J, Tang M, Zhao Y, et al. In chronic spontaneous urticaria, increased galectin⁃9 expression on basophils and eosinophils is linked to high disease activity, endotype⁃specific markers, and response to omalizumab treatment［J］. Allergy, 2024,79（9）:2435⁃2447. doi: 10.1111/all.16239.
［23］	Maurer M, Augustin M, Bauer S, et al. Modelling of patient journey in chronic spontaneous urticaria: increasing awareness and education by shorten patients' disease journey in Germany［J］. J Eur Acad Dermatol Venereol, 2024,38（11）:2093⁃2101. doi: 10.1111/jdv.19940.
［24］	Yuasa A, Yonemoto N, Kamei K, et al. Systematic literature review of the use of productivity losses/gains in cost⁃effectiveness analyses of immune⁃mediated disorders［J］. Adv Ther, 2022,39（12）:5327⁃5350. doi: 10.1007/s12325⁃022⁃02321⁃z.
［25］	Nochaiwong S, Chuamanochan M, Ruengorn C, et al. Cost and cost⁃effectiveness of the management strategies of chronic urticaria: a systematic review［J］. JAMA Dermatol, 2024,160（11）:1225⁃1236. doi: 10.1001/jamadermatol.2024.2863.
［26］	Kaplan A, Lebwohl M, Giménez⁃Arnau AM, et al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances［J］. Allergy, 2023,78（2）:389⁃401. doi: 10. 1111/all.15603.
［27］	Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges［J］. Nat Rev Drug Discov, 2023,22（8）:662⁃680. doi: 10.1038/s41573⁃023⁃00735⁃0.
［28］	Jacobson ME, Seshadri RS, Morimoto R, et al. Early intervention and disease modification in atopic dermatitis⁃the current state of the field and barriers to progress［J］. J Eur Acad Dermatol Venereol, 2024,38（4）:665⁃672. doi: 10.1111/jdv.19699.
［29］	Maurer M, Kolkhir P, Pereira MP, et al. Disease modification in chronic spontaneous urticaria［J］. Allergy, 2024,79（9）:2396⁃2413. doi: 10.1111/all.16243.
［30］	Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic （spontaneous） urticaria: a meta⁃analysis of "real⁃world" evidence［J］. JAMA Dermatol, 2019,155（1）:29⁃38. doi: 10.1001/jamadermatol.2018.3447.
［31］	Maurer M, Ensina LF, Gimenez⁃Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials［J］. Lancet, 2024,403（10422）:147⁃159. doi: 10.1016/S0140⁃6736（23）01684⁃7.
［32］	Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY⁃CSU CUPID）: two randomized, double⁃blind, placebo⁃controlled, phase 3 trials［J］. J Allergy Clin Immunol, 2024,154（1）:184⁃194. doi: 10.1016/j.jaci.2024.01.028.
［33］	Grattan C, Kocatürk E. How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab［J］. Br J Dermatol, 2024,191（2）:153⁃154. doi: 10.1093/bjd/ljae165.
［34］	Jain V, Giménez⁃Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks［J］. J Allergy Clin Immunol, 2024,153（2）:479⁃486. doi: 10.1016/j.jaci.2023. 10.007.
［35］	Min TK, Saini SS. The future of targeted therapy in chronic spontaneous urticaria［J］. Ann Allergy Asthma Immunol, 2024,133（4）:367⁃373. doi: 10.1016/j.anai.2024.05.020.
［36］	Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell⁃mediated diseases［J］. Allergy, 2024,79（1）:37⁃51. doi: 10.1111/all.15850.

[1]	郑雅萱苏惠春. 汗液在胆碱能性荨麻疹中的作用[J]. 中华皮肤科杂志, 2025, 58(6): 573-577.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 中国难治性慢性自发性荨麻疹诊治指南（2025版）[J]. 中华皮肤科杂志, 2025, 58(6): 485-496.
[3]	唐汇洋杨芷样希姚正秋陈邦涛郝飞. 氧化三甲胺参与慢性自发性荨麻疹发病的机制研究[J]. 中华皮肤科杂志, 2025, 58(6): 515-522.
[4]	黄雪薇陈奇权杨显杰陈安祺王欢邓思思翟志芳王娟宋志强. 荨麻疹性血管炎与伴色素沉着慢性自发性荨麻疹的临床与病理特征对比分析[J]. 中华皮肤科杂志, 2025, 58(6): 508-514.
[5]	肖萌赵美茹张新美张俊艳亓玉青王惠平. 慢性自发性荨麻疹患者疾病负担的单中心回顾性分析[J]. 中华皮肤科杂志, 2025, 58(6): 530-535.
[6]	梁碧华陈紫嫣李华平邹荟林天一李晓峰张珞喻李圣信欧珊珊陈教全李润祥朱慧兰. Olink靶向蛋白质组学技术分析慢性自发性荨麻疹患者抗组胺药治疗抵抗相关血清炎症因子[J]. 中华皮肤科杂志, 2025, 58(6): 523-529.
[7]	赵美茹肖萌张新美张俊艳亓玉青王惠平. 奥马珠单抗治疗妊娠期或哺乳期慢性自发性荨麻疹患者8例临床分析[J]. 中华皮肤科杂志, 2025, 58(6): 536-539.
[8]	何泽枝陈嘉珍吴慧沈郝佳朱慧兰李润祥. 中国1990—2021年0 ~ 14岁儿童荨麻疹发病趋势及与空气污染物关系的多模型分析[J]. 中华皮肤科杂志, 2025, 58(6): 540-545.
[9]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[10]	梁高澎杨显杰陈奇权宋志强. 慢性荨麻疹共病的研究现状及进展[J]. 中华皮肤科杂志, 2025, 58(6): 567-572.
[11]	李恩泽陈璐张楚翘姚昱旭焦晴晴季江. 肠道菌群及短链脂肪酸与慢性自发性荨麻疹相关性研究进展[J]. 中华皮肤科杂志, 2025, 58(6): 577-581.
[12]	王伟霞王晨窦进法卞璐宋静卉李振鲁李建国王建波. 遗传性纤维性皮肤异色病伴跟腱挛缩、肌病和肺纤维化：病例报道及基因型与表型关系的文献回顾分析[J]. 中华皮肤科杂志, 2025, 58(4): 356-360.
[13]	叶慧邓仕琳梁景耀张锡宝. 特应性皮炎复发控制与组织驻留记忆性T细胞的相关性研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240192-e20240192.
[14]	王鑫刘丽娟李邻峰. 物理性荨麻疹临床特征：基于多中心医院问卷的横断面调查[J]. 中华皮肤科杂志, 2024, 57(8): 693-697.
[15]	高莹王建才朱芸张建昭仪晓立白晋丽瞿宇晋. 神经纤维瘤病1型患儿22例临床特点及NF1基因变异分析[J]. 中华皮肤科杂志, 2024, 57(7): 637-644.

慢性自发性荨麻疹的疾病管理和疾病修饰：新时代下的需求与展望

Disease management and modification in chronic spontaneous urticaria: needs and prospects in the new era

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

Metrics

本文评价

推荐阅读 10